Study of Insulin Requirement Modeling in Hospitalized Elderly Patients with Type 2 Diabetes at a Late Stage of Stepwise Escalation Therapy.

Abstract:

BACKGROUND:This study explored the relationships between exogenous insulin requirements and endogenous variables in elderly patients with type 2 diabetes (T2D). SUBJECTS AND METHODS:Patients with T2D 65 years of age or older were enrolled for a short hospitalization period in order to start or change their basal-bolus therapy. The following data were collected: age, sex, diabetes duration, body mass index, glycosylated hemoglobin, estimated glomerular filtration rate (eGFR), and triglyceride (TG) levels. RESULTS:Data from 71 elderly T2D patients (31 men/40 women; 75.7 ± 6 years of age) were analyzed by data mining techniques. The total daily dose of insulin (TDI) ranged from 0.24 U/kg to 2.5 U/kg (ratio >1:10). Three clusters of patients were identified: Cluster 1 (n = 22) consisted of older patients (age, 82.05 ± 3.6 years) (P < 0.0001) with a TDI of 0.59 ± 0.21 U/kg/day and lower TG level (1.1 ± 0.4 mmol/L) (P < 0.0001). Cluster 2 (n = 22) consisted of patients with a TDI of 0.71 ± 0.24 U/kg/day with a higher eGFR (75.3 ± 18.8 mL/min) (P < 0.001) and a shorter duration of diabetes (13.6 ± 6.4 years) (P < 0.001). Cluster 3 (n = 27) consisted of patients with a larger proportion of macroangiopathic complications (P < 0.05), having a TDI of 1.31 ± 0.54 U/kg/day, higher TG level (2.2 ± 0.7 mmol/L) (P < 0.001), and lower eGFR (46.3 ± 16 mL/min). The average basal-bolus ratio was 43%/57% with a maximum bolus requirement due to carbohydrate intake at breakfast. CONCLUSIONS:Insulin requirements in elderly T2D patients vary widely. Age, TG level, and eGFR appeared to be the most predictive factors of TDI. Because of the small sample size, further studies would be required to extrapolate these results.

journal_name

Diabetes Technol Ther

authors

Nourizadeh-Sedaghati A,Herbin M,Lukas-Croisier C,Novella JL,Delemer B

doi

10.1089/dia.2015.0044

subject

Has Abstract

pub_date

2016-05-01 00:00:00

pages

308-15

issue

5

eissn

1520-9156

issn

1557-8593

journal_volume

18

pub_type

杂志文章
  • Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions.

    abstract:: Background: The objective of this study was to assess the safety and performance of the Omnipod® personalized model predictive control (MPC) algorithm in adults, adolescents, and children aged ≥6 years with type 1 diabetes (T1D) under free-living conditions using an invest...

    journal_title:Diabetes technology & therapeutics

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1089/dia.2019.0286

    authors: Sherr JL,Buckingham BA,Forlenza GP,Galderisi A,Ekhlaspour L,Wadwa RP,Carria L,Hsu L,Berget C,Peyser TA,Lee JB,O'Connor J,Dumais B,Huyett LM,Layne JE,Ly TT

    更新日期:2020-03-01 00:00:00

  • Continuous Glucose Monitoring, Glycemic Variability, and Excessive Fetal Growth in Pregnancies Complicated by Type 1 Diabetes.

    abstract:BACKGROUND:To examine trimester-specific associations among glycemic variability, fetal growth, and birthweight in pregnancies with type 1 diabetes mellitus (Type 1 DM). METHODS:In this retrospective cohort study of 41 pregnant women with Type 1 DM, we used continuous glucose monitoring (CGM) data to calculate glycemi...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2017.0443

    authors: Mulla BM,Noor N,James-Todd T,Isganaitis E,Takoudes TC,Curran A,Warren CE,O'Brien KE,Brown FM

    更新日期:2018-06-01 00:00:00

  • Repeatability of indices of insulin sensitivity and secretion from standard liquid meal tests in subjects with type 2 diabetes mellitus or normal or impaired fasting glucose.

    abstract:BACKGROUND:The objective of this investigation was to evaluate the test-retest repeatability of insulin sensitivity and secretion indices derived from liquid meal tolerance tests (MTTs) in subjects with normal fasting glucose (NFG) (n = 20), impaired fasting glucose (IFG) (n = 20), or type 2 diabetes mellitus (n = 38)....

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1089/dia.2010.0083

    authors: Maki KC,Rains TM,Dicklin MR,Bell M

    更新日期:2010-11-01 00:00:00

  • Performance evaluation of the GlucoDr plus glucometer.

    abstract:BACKGROUND:Because strict glucose control is important for reducing the complications of diabetes, the self-monitoring of blood glucose is one of the fundamental treatment modalities. Many glucometers have been developed. In the present study, we evaluated a new glucometer: GlucoDr Plus (Allmedicus, Anyang, Gyeonggi-do...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2009.0134

    authors: Ko DH,Lim S,Song SH,Choi SH,Park YJ,Park KU,Jang HC,Song J

    更新日期:2010-04-01 00:00:00

  • Self-monitoring of blood glucose in diabetes: from evidence to clinical reality in Central and Eastern Europe--recommendations from the international Central-Eastern European expert group.

    abstract::Self-monitoring of blood glucose (SMBG) is universally considered to be an integral part of type 1 diabetes management and crucial for optimizing the safety and efficacy of complex insulin regimens. This extends to type 2 diabetes patients on intensive insulin therapy, and there is also a growing body of evidence sugg...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1089/dia.2013.0302

    authors: Czupryniak L,Barkai L,Bolgarska S,Bronisz A,Broz J,Cypryk K,Honka M,Janez A,Krnic M,Lalic N,Martinka E,Rahelic D,Roman G,Tankova T,Várkonyi T,Wolnik B,Zherdova N

    更新日期:2014-07-01 00:00:00

  • Duration of Infusion Set Survival in Lipohypertrophy Versus Nonlipohypertrophied Tissue in Patients with Type 1 Diabetes.

    abstract:BACKGROUND:Improved insulin infusion set survival and faster insulin action are important issues for pump users and for the development of an artificial pancreas. The current recommendation is to change infusion sets every 3 days. Our objectives were to determine the effect of lipohypertrophy (LH) on infusion set survi...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1089/dia.2015.0432

    authors: Karlin AW,Ly TT,Pyle L,Forlenza GP,Messer L,Wadwa RP,DeSalvo DJ,Payne SL,Hanes S,Clinton P,Maahs DM,Buckingham B

    更新日期:2016-07-01 00:00:00

  • Oral insulin product hexyl-insulin monoconjugate 2 (HIM2) in type 1 diabetes mellitus: the glucose stabilization effects of HIM2.

    abstract::This study was designed to determine plasma glucose and insulin levels after administration of three escalating doses of the oral insulin product hexyl-insulin monoconjugate 2 (HIM2) in fasting, insulin-deprived adult patients with type 1 diabetes. The study was also designed to assess the safety of the product. Sixte...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/152091502760306544

    authors: Clement S,Still JG,Kosutic G,McAllister RG

    更新日期:2002-01-01 00:00:00

  • The "glucose pentagon": assessing glycemic control of patients with diabetes mellitus by a model integrating different parameters from glucose profiles.

    abstract::Measuring the hemoglobin A(1c) (HbA(1c)) is the standard-of-care method to assess long-term glycemic control of patients with diabetes, describing the average glycemic level. However, the HbA(1c) does not reflect acute fluctuations in glucose levels. Variability of glycemia probably has an impact on the development of...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2008.0119

    authors: Thomas A,Schönauer M,Achermann F,Schnell O,Hanefeld M,Ziegelasch HJ,Mastrototaro J,Heinemann L

    更新日期:2009-06-01 00:00:00

  • Continuous glucose monitoring and diabetes health outcomes: a critical appraisal.

    abstract::This paper presents a critical review of continuous glucose monitoring studies that address accuracy, utility in assessing glucose variability, detection of hypoglycemia for improved metabolic control or reduced glucose variability, impact on quality of life, reduced fear of hypoglycemia, and applicability in helping ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1089/dia.2007.0261

    authors: Reach G

    更新日期:2008-04-01 00:00:00

  • The StatStrip glucose monitor is suitable for use during hyperinsulinemic euglycemic clamps in a pediatric population.

    abstract:BACKGROUND:The hyperinsulinemic euglycemic clamp is the gold standard for assessment of insulin resistance and requires frequent, accurate measurements of blood glucose concentrations, typically utilizing the YSI 2300 STAT Plus™ glucose analyzer (YSI, Inc., Yellow Springs, OH). Despite its accuracy, the YSI has several...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2013.0288

    authors: Lindquist KA,Chow K,West A,Pyle L,Isbell TS,Cree-Green M,Nadeau KJ

    更新日期:2014-05-01 00:00:00

  • Hypoglycemia prediction and detection using optimal estimation.

    abstract::Patients with diabetes play with a double-edged sword when it comes to deciding glucose and A1c target levels. On the one side, tight control has been shown to be crucial in avoiding long-term complications; on the other, tighter control leads to an increased risk of iatrogenic hypoglycemia, which is compounded when h...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2005.7.3

    authors: Palerm CC,Willis JP,Desemone J,Bequette BW

    更新日期:2005-02-01 00:00:00

  • System Accuracy Evaluation of Different Blood Glucose Monitoring Systems Following ISO 15197:2013 by Using Two Different Comparison Methods.

    abstract:BACKGROUND:Adherence to established standards (e.g., International Organization for Standardization [ISO] 15197) is important to ensure comparable and sufficient accuracy of systems for self-monitoring of blood glucose (SMBG). Accuracy evaluation was performed for different SMBG systems available in Europe with three r...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2015.0085

    authors: Freckmann G,Link M,Schmid C,Pleus S,Baumstark A,Haug C

    更新日期:2015-09-01 00:00:00

  • Is angiotensin I-converting enzyme a "master" disease gene?

    abstract::Clustering of diseases has been appreciated by health insurers and epidemiologists for some time. Co-morbidity suggests shared pathways of disease. It is by now well agreed that common diseases have a strong genetic component. Here we present evidence that the angiotensin I-converting enzyme (ACE) deletion/deletion (D...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/152091502320798321

    authors: Moskowitz DW

    更新日期:2002-01-01 00:00:00

  • Efficacy and Safety of SGLT2 Inhibitors in Type 1 Diabetes After the Introduction of an Off-Label Use Protocol for Clinical Practice.

    abstract:: Aims: We evaluated the real-life efficacy and safety of empagliflozin in combination with optimized insulin therapy in patients with type 1 diabetes (T1D). Methods: This was a prospective study, including 27 patients with T1D t...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2019.0316

    authors: Bayona Cebada A,Nattero-Chávez L,Alonso Díaz S,Escobar-Morreale HF,Luque-Ramírez M

    更新日期:2020-03-01 00:00:00

  • Accuracy of continuous glucose monitoring during exercise in type 1 diabetes pregnancy.

    abstract:BACKGROUND:Performance of continuous glucose monitors (CGMs) may be lower when glucose levels are changing rapidly, such as occurs during physical activity. Our aim was to evaluate accuracy of a current-generation CGM during moderate-intensity exercise in type 1 diabetes (T1D) pregnancy. SUBJECTS AND METHODS:As part o...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2012.0292

    authors: Kumareswaran K,Elleri D,Allen JM,Caldwell K,Nodale M,Wilinska ME,Amiel SA,Hovorka R,Murphy HR

    更新日期:2013-03-01 00:00:00

  • Continuous glucose monitoring pilot in low-income type 1 diabetes patients.

    abstract:BACKGROUND:Continuous glucose monitoring (CGM) has been shown to be a valuable tool to improve glycemic control in patients with diabetes. The objective of this pilot study was to develop and implement CGM in an existing diabetes clinic for low-income patients on multiple daily injections. SUBJECTS AND METHODS:This wa...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1089/dia.2013.0072

    authors: Sequeira PA,Montoya L,Ruelas V,Xing D,Chen V,Beck R,Peters AL

    更新日期:2013-10-01 00:00:00

  • Lasers and diabetic retinopathy: the art of gentle destruction.

    abstract::Laser retinal photocoagulation represents the primary therapy for the potentially blinding manifestations of diabetic retinopathy. Advances in laser therapy for diabetic eye disease have arisen from the convergence of laser technology and clinical ophthalmology. In this review, the basis of laser therapy in diabetic r...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1089/152091599317396

    authors: Petrovic V,Bhisitkul RB

    更新日期:1999-07-01 00:00:00

  • Evaluation of hemoglobin A1c criteria to assess preoperative diabetes risk in cardiac surgery patients.

    abstract:OBJECTIVE:Hemoglobin A1c (A1C) has recently been recommended for diagnosing diabetes mellitus and diabetes risk (prediabetes). Its performance compared with fasting plasma glucose (FPG) and 2-h post-glucose load (2HPG) is not well delineated. We compared the performance of A1C with that of FPG and 2HPG in preoperative ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2011.0074

    authors: Gianchandani RY,Saberi S,Zrull CA,Patil PV,Jha L,Kling-Colson SC,Gandia KG,DuBois EC,Plunkett CD,Bodnar TW,Pop-Busui R

    更新日期:2011-12-01 00:00:00

  • Frequency of the dawn phenomenon in type 2 diabetes: implications for diabetes therapy.

    abstract::This study was designed to assess the frequency of the dawn phenomenon in patients with type 2 diabetes. A secondary aim was to examine the influence of varying treatment regimens on the frequency of the dawn phenomenon. The dawn phenomenon was defined as a rise in plasma glucose levels of > or = 0.5 mmol/L (10 mg/dL)...

    journal_title:Diabetes technology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1089/152091502320798213

    authors: Carroll MF,Hardy KJ,Burge MR,Schade DS

    更新日期:2002-01-01 00:00:00

  • Systemic effects of shock and resuscitation monitored by visible hyperspectral imaging.

    abstract::Hyperspectral imaging (HSI) has been useful in monitoring several medical conditions, which to date have generally involved local changes in skin oxygenation of isolated regions of interest such as skin flaps or small burns. Here, by contrast, we present a study in which HSI was used to assess the local cutaneous mani...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/152091503322527058

    authors: Gillies R,Freeman JE,Cancio LC,Brand D,Hopmeier M,Mansfield JR

    更新日期:2003-01-01 00:00:00

  • Point accuracy of interstitial continuous glucose monitoring during exercise in type 1 diabetes.

    abstract:BACKGROUND:Previous studies of aerobic exercise have found lower sensor accuracy during exercise. Whether or not resistance exercise would also be associated with lower sensor accuracy has not yet been examined. This study sought to investigate the accuracy of continuous glucose monitoring sensor values at rest, during...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2012.0182

    authors: Yardley JE,Sigal RJ,Kenny GP,Riddell MC,Lovblom LE,Perkins BA

    更新日期:2013-01-01 00:00:00

  • Impact of glycemic control on heart rate variability in youth with type 1 diabetes: the SEARCH CVD study.

    abstract:AIM:This study explored the role of glycemic control on cardiac autonomic function, measured by heart rate variability (HRV), in youth with type 1 diabetes. PATIENTS AND METHODS:A retrospective cohort of 345 youth with type 1 diabetes (mean age, 18.5 years; duration, 10 years) participating in the SEARCH for Diabetes ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1089/dia.2013.0147

    authors: Jaiswal M,Fingerlin TE,Urbina EM,Wadwa RP,Talton JW,D'Agostino RB Jr,Hamman RF,Daniels SR,Marcovina SM,Dolan LM,Dabelea D

    更新日期:2013-12-01 00:00:00

  • Patient perceptions of using the OmniPod system compared with conventional insulin pumps in young adults with type 1 diabetes.

    abstract:AIMS:This study evaluated treatment satisfaction, comfort, and function using the wireless OmniPod™ Insulin Management System (Insulet Corp., Bedford, MA) compared with conventional (infusion set) insulin pumps in young adults with type 1 diabetes. RESEARCH DESIGN AND METHODS:Twenty-nine patients (age, 24.0 ± 5.1 year...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1089/dia.2011.0228

    authors: Lebenthal Y,Lazar L,Benzaquen H,Shalitin S,Phillip M

    更新日期:2012-05-01 00:00:00

  • Determining clinical and psychological benefits and barriers with continuous glucose monitoring therapy.

    abstract:BACKGROUND:Preventing the complications of diabetes requires tight control and minimizing blood glucose fluctuation. Pursuing these goals increases the risk of severe hypoglycemia. The authors hoped to identify if using continuous glucose monitoring (CGM) decreased the incidence of severe hypoglycemia, resulted in less...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2009.0121

    authors: Halford J,Harris C

    更新日期:2010-03-01 00:00:00

  • The effect of local subcutaneous delivery of vascular endothelial growth factor on the function of a chronically implanted amperometric glucose sensor.

    abstract::The foreign body capsule that forms around implanted devices such as glucose sensors is hypovascular and has limited permeability to glucose. Such a capsule may function better if well vascularized. We hypothesized that capsular vascularization achieved by local release of vascular endothelial growth factor (VEGF) wou...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/152091504773731320

    authors: Ward WK,Wood MD,Casey HM,Quinn MJ,Federiuk IF

    更新日期:2004-04-01 00:00:00

  • Management of patients with diabetes through information technology: tools for monitoring and control of the patients' metabolic behavior.

    abstract:BACKGROUND:The junction of telemedicine home monitoring with multifaceted disease management programs seems nowadays a promising direction to combine the need for an intensive approach to deal with diabetes and the pressure to contain the costs of the interventions. Several projects in the European Union and the United...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2004.6.567

    authors: Bellazzi R,Arcelloni M,Ferrari P,Decata P,Hernando ME,García A,Gazzaruso C,Gómez EJ,Larizza C,Fratino P,Stefanelli M

    更新日期:2004-10-01 00:00:00

  • Accuracy of glycemic measurements in the critically ill.

    abstract:BACKGROUND:Recent evidence emphasizes the importance of maintaining normoglycemia in critically ill patients to reduce morbidity and mortality. Different analytical methods of varying accuracy exist for obtaining and measuring blood glucose in critically ill patients. The purpose of this study was to determine if there...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2008.0263

    authors: Slater-MacLean L,Cembrowski G,Chin D,Shalapay C,Binette T,Hegadoren K,Newburn-Cook C

    更新日期:2008-06-01 00:00:00

  • Incretin mimetics and dipeptidyl peptidase-IV inhibitors: a review of emerging therapies for type 2 diabetes.

    abstract::Type 2 diabetes is thought to develop as a result of progressive beta-cell dysfunction in the setting of insulin resistance, leading to increased risks of microvascular and macrovascular complications. Type 2 diabetes is currently treated with diet and exercise, followed by oral drug therapy, and finally exogenous ins...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1089/dia.2006.8.385

    authors: Kendall DM,Kim D,Maggs D

    更新日期:2006-06-01 00:00:00

  • Randomized Evaluation of Glycemic Control in the Medical Intensive Care Unit Using Real-Time Continuous Glucose Monitoring (REGIMEN Trial).

    abstract:BACKGROUND AND OBJECTIVE:Hyperglycemia occurs commonly in patients admitted to medical intensive care units (MICUs). Whether real-time (RT) continuous glucose monitoring (CGM) improves glycemic control and variability and reduces hypoglycemia in severely ill MICU patients with an Acute Physiology and Chronic Health Eva...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1089/dia.2015.0151

    authors: De Block CE,Gios J,Verheyen N,Manuel-y-Keenoy B,Rogiers P,Jorens PG,Scuffi C,Van Gaal LF

    更新日期:2015-12-01 00:00:00

  • Glycemic control and perinatal outcomes of pregnancies complicated by type 1 diabetes: influence of continuous subcutaneous insulin infusion and lispro insulin.

    abstract:AIMS:This study compared glycemic control and maternal and fetal outcomes in pregnant women with type 1 diabetes mellitus (T1DM) treated with multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII) using regular (RI) or lispro (LP) insulin. METHODS:Three hundred fifteen consecutive singleton...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2010.0111

    authors: Chico A,Saigi I,García-Patterson A,Santos MD,Adelantado JM,Ginovart G,de Leiva A,Corcoy R

    更新日期:2010-12-01 00:00:00